How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Optilume for treating recurrent bulbar urethral strictures

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Optilume is recommended as an option to treat recurrent bulbar urethral strictures in adults only if comparative data is collected on:

  • patient-reported outcome measures

  • reintervention rates.

1.2 Find out details of required outcomes in further research.

Why the committee made these recommendations

Optilume done in an outpatient setting could reduce the waiting times for treatment of recurrent bulbar urethral strictures. The clinical evidence shows that Optilume is effective in the short term. But how effective and safe it is in the long term is uncertain. So, more long-term data collection is needed on retreatment rates and patient-reported outcomes.